These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30589629)

  • 21. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of a Predictive Model to Identify Individuals Likely to Have Undiagnosed Chronic Obstructive Pulmonary Disease Using an Administrative Claims Database.
    Moretz C; Zhou Y; Dhamane AD; Burslem K; Saverno K; Jain G; Devercelli G; Kaila S; Ellis JJ; Hernandez G; Renda A
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1149-59. PubMed ID: 26679964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a Therapeutic Interchange from Fluticasone/Salmeterol to Mometasone/Formoterol in Patients with Chronic Obstructive Pulmonary Disease.
    Yip E; Karimi S; Pien LT
    J Manag Care Spec Pharm; 2016 Apr; 22(4):316-23. PubMed ID: 27023685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease.
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    J Manag Care Spec Pharm; 2018 Mar; 24(3):265-279. PubMed ID: 29485951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
    Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex Differences in Veterans Admitted to the Hospital for Chronic Obstructive Pulmonary Disease Exacerbation.
    Bade BC; DeRycke EC; Ramsey C; Skanderson M; Crothers K; Haskell S; Bean-Mayberry B; Brandt C; Bastian LA; Akgün KM
    Ann Am Thorac Soc; 2019 Jun; 16(6):707-714. PubMed ID: 30822098
    [No Abstract]   [Full Text] [Related]  

  • 28. The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study.
    Adibi A; Sin DD; Safari A; Johnson KM; Aaron SD; FitzGerald JM; Sadatsafavi M
    Lancet Respir Med; 2020 Oct; 8(10):1013-1021. PubMed ID: 32178776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting.
    Bogart M; Glassberg MB; Reinsch T; Stanford RH
    Respir Med; 2018 Dec; 145():138-144. PubMed ID: 30509702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
    Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
    J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication Therapy Management: 10 Years of Experience in a Large Integrated Health Care System.
    de Oliveira DR; Brummel AR; Miller DB
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1057-1066. PubMed ID: 32857651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States.
    Bogart M; Germain G; Laliberté F; Lejeune D; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1575-1586. PubMed ID: 37521022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
    Pauly NJ; Talbert JC; Brown J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    Iyer AS; Bhatt SP; Garner JJ; Wells JM; Trevor JL; Patel NM; Kirkpatrick d; Williams JC; Dransfield MT
    Ann Am Thorac Soc; 2016 Feb; 13(2):197-203. PubMed ID: 26599286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
    Fraser A; Poole P
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).
    Yang T; Cai B; Cao B; Kang J; Wen F; Chen Y; Jian W; Wang C
    Ther Adv Respir Dis; 2023; 17():17534666231167353. PubMed ID: 37073797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.